Published online Oct 6, 2023. doi: 10.12998/wjcc.v11.i28.6774
Peer-review started: August 8, 2023
First decision: August 24, 2023
Revised: August 31, 2023
Accepted: September 14, 2023
Article in press: September 14, 2023
Published online: October 6, 2023
Processing time: 48 Days and 8.5 Hours
Autologous serum eye drops (ASEDs) have emerged as a groundbreaking solution for managing dry eye syndrome (DES).
This study aimed to evaluate the safety and effectiveness of ASEDs compared to traditional treatments for moderate-to-severe DES.
The main objective of this study was to evaluate the safety and effectiveness of ASEDs compared to conventional artificial tears in the treatment of moderate-to-severe DES.
A multi-centered randomized controlled trial (RCT) was conducted involving 240 patients from three ophthalmology clinics in China. The primary outcome was the change in the ocular surface disease index (OSDI) score, with secondary outcomes including tear break-up time (TBUT), Schirmer I test, corneal fluorescein staining (CFS), and conjunctival impre
Results showed that ASEDs were significantly more effective than artificial tears in improving these measures without severe adverse events. ASEDs are considered a valuable alternative therapy for DES patients unresponsive to traditional treatments.
The study demonstrated that ASEDs are both more effective and safer than conventional artificial tears for the treatment of moderate-to-severe DES. The ASEDs group exhibited significant improvements in the OSDI score, TBUT, Schirmer I test, CFS, and CIC compared to the artificial tears group. The average difference in the OSDI score between the two groups was substantial, indicating a notable improvement in the ASEDs group. Importantly, no severe adverse events were reported in either group. These findings establish ASEDs as a valuable alternative or supplementary therapy for DES patients who do not respond well to traditional treatments.
The research findings highlight the potential of ASEDs as a promising therapy for moderate-to-severe DES. Further studies could explore the long-term effects of ASEDs and compare their efficacy with other emerging treatments. Additionally, investigating the underlying mechanisms of action of ASEDs and identifying patient characteristics that predict treatment response would contribute to personalized treatment approaches. Cost-effectiveness analyses and evaluations in diverse populations would provide valuable insights into the broader applicability of ASEDs. Further